TSE/BSE + Allergen-Free Statements — What Cosmetic Actives Documentation Actually Needs to Cover

Two documentation classes that surface in nearly every cosmetic raw material qualification: the TSE/BSE statement (concerning transmissible spongiform encephalopathy and bovine spongiform encephalopathy risk) and the allergen-free statement (concerning the major food and cosmetic allergens). For peptide actives specifically — most of which are synthetic and animal-origin-free — the documentation is relatively straightforward, but the format and content expectations are not always obvious to brand-side QA reviewing supplier paperwork for the first time.

What TSE/BSE concerns are

Transmissible Spongiform Encephalopathy (TSE) is a class of neurodegenerative diseases that includes Bovine Spongiform Encephalopathy (BSE, "mad cow disease"), Scrapie in sheep, Chronic Wasting Disease in deer, and Creutzfeldt-Jakob Disease (CJD) in humans. The diseases are caused by misfolded prion proteins that propagate by inducing misfolding in normal proteins they encounter.

The relevance to cosmetics: ingredients derived from animals that can carry TSE/BSE-causative prions (primarily bovine, ovine, and certain other ruminants) carry potential contamination risk. The FDA's 2016 final rule on use of materials derived from cattle in human food and cosmetics establishes specific restrictions on what cattle-derived materials can be used. Equivalent rules apply in the EU, UK, and most major markets.

For peptide actives: - Synthetic peptides — produced by chemical solid-phase synthesis from individual amino acids. The starting amino acids may be of various origins (fermentation, chemical synthesis, plant extraction); none typically carry TSE/BSE risk - Recombinant peptides — produced by genetically engineered cells (bacteria, yeast, mammalian). Risk depends on the cell line and the growth medium; mammalian cell-line products grown in bovine-serum-supplemented media have potential risk and require declaration - Animal-extracted peptides — extracted from animal tissues (insulin from porcine pancreas, certain growth-factor preparations from bovine or ovine sources). Higher risk; requires specific certification on source country, age of animals, tissue type, and processing controls

Most modern cosmetic peptide actives — including all of those Pepoderma supplies — are synthetic, with no animal-origin starting materials. The TSE/BSE statement for these is short: "synthetic origin, no animal-derived materials in the supply chain."

What a complete TSE/BSE statement looks like

For a synthetic peptide active, the statement should include:

1. **Origin declaration** — "The product is manufactured by solid-phase peptide synthesis from individually purchased amino acid building blocks of [synthetic / fermentation / plant] origin. No animal-derived materials are used in the synthesis, purification, or packaging of this product."
2. **Manufacturing site location** — geographic location of the synthesis facility (relevant because some countries have additional reporting requirements based on facility location)
3. **Effective date and signature** — the date the statement is valid as of, signed by a designated quality official at the manufacturer

For a recombinant peptide, additional content: - Cell line used (bacterial / yeast / mammalian) - Cell-line growth medium composition (specifically whether bovine serum or other animal-derived medium components are used) - Downstream processing steps that would remove any potential prion contamination (typically column chromatography with specified residual prion clearance)

For an animal-extracted peptide, much more extensive content: - Source country of the animal tissue (some countries are higher BSE-risk than others; OIE classifications matter) - Age of animals at slaughter (younger animals = lower prion risk) - Tissue type used and whether high-risk tissues (CNS, intestine) are involved - Processing conditions (specific time/temperature combinations that achieve prion clearance) - Third-party certification reference if applicable

What an allergen-free statement actually means

Allergen documentation differs from TSE/BSE because the allergens of concern are food allergens (regulated under food safety frameworks) being declared for cosmetic safety reasons. The major allergens covered:

• Gluten (wheat, barley, rye)
• Lactose / dairy
• Soy
• Tree nuts
• Peanuts
• Sesame
• Shellfish / fish
• Eggs
• Sulphites (above defined thresholds)

For peptide actives — almost all of which are synthetic — the allergen risk is from cross-contamination during manufacturing rather than the active itself. The statement covers:

1. **Direct presence**: confirmation that the active itself does not contain any of the major allergens
2. **Cross-contamination assessment**: declaration of whether the manufacturing facility processes any of the major allergens in adjacent operations
3. **Cleaning and changeover protocols**: brief description of the cleaning protocols between products that would handle different allergens
4. **Testing**: whether allergen-specific testing (PCR or ELISA-based) is performed on the active to confirm absence

For synthetic peptide manufacturing facilities, allergen cross-contamination risk is generally low because the facility processes individual amino acids and synthetic reagents, not bulk food ingredients. The statement is usually short: "The manufacturing facility does not process any of the major allergens. Direct cross-contamination is not expected. Per-lot allergen testing is available on request."

What separates a useful statement from a checklist statement

A useful TSE/BSE or allergen statement gives the brand or regulator enough information to assess risk independently. A checklist statement just asserts compliance without supporting detail.

Checklist statement (less useful): "This product is TSE/BSE-free and allergen-free."

Useful statement: "This product is manufactured by solid-phase peptide synthesis at [facility location] from individually purchased amino acid building blocks of synthetic origin. No animal-derived materials are used. The manufacturing facility does not process any of the major food allergens (gluten, dairy, soy, tree nuts, peanuts, sesame, shellfish, eggs); cross-contamination is not expected. Allergen testing by PCR or ELISA is available on request. Effective date: [date]. Signed by: [QA Director name]."

The useful version takes more space but it actually means something. The checklist version is what's audit-flagged when an enforcement authority reviews supplier documentation.

What markets require what

For an indie brand selling into multiple markets, a single comprehensive supplier statement that covers all the bases is more efficient than market-specific statements. Most major cosmetic active suppliers provide a unified statement formatted to satisfy all major markets.

What Pepoderma ships and what's documented under NDA

Every Pepoderma cosmetic-grade peptide active ships with: - TSE/BSE statement — synthetic origin declaration, manufacturing facility location, signed and dated by QA - Allergen statement — facility allergen-handling declaration, cross-contamination assessment, testing availability - Animal testing statement — confirmation that the product has not been tested on animals (relevant for EU cosmetic regulation post-2013 and other markets with cruelty-free requirements)

Available on request for specific market registration support: - Market-specific localized statements (Chinese language for NMPA registration, Japanese language for PMDA submissions, etc.) - Per-lot allergen testing reports (PCR-based) - Additional declarations specific to particular markets (GMO-free, vegan, halal, kosher) where the underlying chemistry supports them - Third-party certifications (specific allergen testing accreditations) on request

The standard package satisfies most market requirements at the supplier-documentation level. The brand's Responsible Person, Product Information File, and finished-product safety assessment then build on this with the brand-side documentation for finished-product compliance.